PROCEPT BioRobotics Corp
PROCEPT BioRobotics develops, manufactures and sells robotic systems and Aquablation therapy for minimally invasive urologic surgery, initially focused on treating benign prostatic hyperplasia, or BPH. Its products are the AquaBeam Robotic System and the next-generation HYDROS Robotic System. Both use image guidance, personalized treatment planning, automated robotics and a heat-free waterjet to remove prostate tissue. The HYDROS system includes the FirstAssist AI feature. PROCEPT sells primarily to hospitals in the United States, and also to distribution partners, ambulatory surgery centers and leasing companies. It sells through a direct sales organization in the United States and through direct sales and distribution partners in some international regions. The systems use single-use disposable handpieces, and PROCEPT also offers sales-type leasing arrangements. As of December 31, 2025, its global install base was 912 systems, including 718 in the United States. PROCEPT BioRobotics is headquartered in San Jose, California.
No enriched coverage for $PRCT in the last 7 days.
No SEC Form 4 filings for $PRCT in the last 30 days.
See all $PRCT insider activity →PROCEPT BioRobotics (PRCT) will release Q3 2026 earnings after market close on Nov. 4, 2026, followed by a conference call. The announcement is a routine scheduling notice.
PROCEPT BioRobotics Corp (PRCT) appointed Dr. Michael Mack as a Class II, independent director, increasing its board size from nine to ten members. Mack is a cardiac surgeon with extensive experience and over 1,100 peer-reviewed publications.
PROCEPT BioRobotics Corp (PRCT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 2, 2026, the board of directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) approved (i) an
Recent PRCT coverage spans earnings, corporate actions and financial news.
The scheduling notice provides no new financial metrics or guidance, so immediate price impact is expected to be minimal.
Board expansion may be viewed as a modest governance improvement, but no immediate operational impact.
Board expansion and new independent director may be viewed positively by investors seeking governance strength.
The amendment provides additional financing runway but does not change loan size or covenants.
The filing is a fresh insider buy signal, but it is not a fundamental catalyst like earnings, guidance, or a deal.
AlphAI scores every news story that mentions PRCT with an AI model for sentiment and relevance, and aggregates insider trades from PROCEPT BioRobotics Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
PROCEPT BioRobotics (PRCT) will release Q3 2026 earnings after market close on Nov. 4, 2026, followed by a conference call. The announcement is a routine scheduling notice.
1 min readPROCEPT BioRobotics Corp (PRCT) appointed Dr. Michael Mack as a Class II, independent director, increasing its board size from nine to ten members. Mack is a cardiac surgeon with extensive experience and over 1,100 peer-reviewed publications.
1 min readPROCEPT BioRobotics Corp (PRCT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 2, 2026, the board of directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) approved (i) an
1 min readPROCEPT BioRobotics Corp (PRCT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On September 23, 2026, PROCEPT BioRobotics Corporation (the “Company”) entered into a Third Amendment to Loan and Security Agreement (the “Third Amendment”) with Canadian Imperial Bank of Commerce (“CIBC”), which amends the Loa
1 min readWood Larry L (President, CEO) purchased 23,900 indirectly-held shares of PROCEPT BioRobotics Corp (PRCT) at $20.85 ($0.50M total) on 2026-08-07.
2 min readProcept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.
6 min readThe acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.
6 min readPROCEPT BioRobotics (Nasdaq: PRCT) said it will release second-quarter 2026 financial results after market close on Aug. 4, 2026, and hold a conference call at 4:30 p.m. ET. The company noted its AQUABEAM and HYDROS robotic systems used for Aquablation therapy in urology.
1 min readPROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.
4 min readPROCEPT BioRobotics Corp (PRCT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. prct-20260609 0001588978 false 0001588978 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
2 min read
